Company: MDCXW
Filing Date: 2025-08-12
Form Type: 253G2
Source: 0001062993-25-014090
Chunk: 33

Company: Medicus Pharma Ltd.
Filing Date: 2025-08-12
Form: 253G2
Chunk 33
---
 the Investor and its affiliates at any one time will not exceed 4.99% of the then-outstanding common shares. Common shares issued and sold to the Investor under the SEPA will be priced at 97% of the market price (as defined in the SEPA) of the common shares during a specified three-day pricing period. The Company reserves the right to set a minimum acceptable price for the common share issuances. Cash flows

|                                       |     | For the six months ended June 30 
                             2025 |   |     |       2024 |   |     |            |   |
|:--------------------------------------|:----|---------------------------------:|:--|:----|-----------:|:--|:----|-----------:|:--|
|                                       |     |                                $ |   |     |          $ |   |     |     Change |   |
| Cash used in operating activities     |     |                       (9,409,825 | ) |     | (3,953,639 | ) |     | (5,456,186 | ) |
| Cash provided by financing activities |     |                       14,915,048 |   |     | 10,642,500 |   |     |  4,272,548 |   |
| Net change in cash during the period  |     |                        5,505,223 |   |     |  6,688,861 |   |     | (1,183,638 | ) |
| Cash, beginning of the period         |     |                        4,164,323 |   |     |  1,719,338 |   |     |  2,444,985 |   |
| Cash, end of the period               |     |                        9,669,546 |   |     |  8,408,199 |   |     |  1,261,347 |   |

Cash flows used in operating activities Cash flows used in operating activities for the six months ended June 30, 2025 were $9,409,825 compared to cash flows used in operating activities of $3,953,639 for the six months ended June 30, 2024. The increase is primarily due to increased spending on research and development activities for our SKNJCT-003 study and trials and increased general and administrative expenses related to our IPO and resulting U.S. reporting obligations, along with multiple financing and other transactional activities. Cash